GT Biopharma regains Nasdaq compliance: what it means for GT Biopharma stock

Published on 10/05/2026 at 06:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nasdaq restored compliance September 22, 2026 after 10 sessions above USD 1.00. GT Biopharma stock had USD 7.7 million market value October 2, 2026.

GTBP, US36254L4077, Illustration mit AI erstellt.

GT Biopharma regained compliance with Nasdaq's minimum bid requirement on September 22, 2026, after its common stock maintained a closing bid above USD 1.00 for 10 consecutive business days, according to the SEC filing. What it means for GT Biopharma stock is straightforward: the listing threat has eased, but the company still depends on clinical execution and financing.

Compliance removes a listing hurdle

GT Biopharma had previously received an additional 180-calendar-day compliance period ending November 16, 2026. The September 22 notice closed that specific minimum-bid issue after the stock stayed above the USD 1.00 threshold for 10 sessions.

The filing also records the earlier problem: the common stock had closed below USD 1.00 for 30 consecutive business days. The restored status therefore marks a measurable change in listing position, rather than a change to the company's research pipeline or financial results.

Clinical pipeline remains the next test

GT Biopharma's investor-relations page lists Q2 2026 results dated June 30, 2026 and a September 15, 2026 update on a potential new indication for GTB-5550, a B7-H3-targeted natural killer cell engager, according to GT Biopharma. The program's development milestones remain the operating factor behind the equity story.

GT Biopharma is a clinical-stage biotechnology company developing immuno-oncology treatments through its TriKE platform. Its pipeline includes GTB-3650 for CD33-expressing blood cancers and GTB-5550 for B7-H3-expressing solid tumors, placing trial progress ahead of commercial revenue as the central business measure.

Market value remains tightly priced

On Nasdaq, GTBP was last at USD 6.10 on October 2, 2026 at 4:00 p.m. ET. The company had a market capitalization of USD 7.7 million, while its 52-week range was USD 4.91 to USD 34.25, putting the latest Nasdaq quote 82.19 percent below the yearly high.

That valuation shows why listing compliance matters for the company: the equity remains a small-cap biotechnology position whose value depends heavily on clinical progress, capital access and continued exchange eligibility. The September 22 filing resolves one immediate exchange condition, while the June 30 reporting period and the September 15 pipeline update define the next evidence points.

Nasdaq listing and market context

GT Biopharma, Inc. trades under ticker GTBP on Nasdaq and operates in the Healthcare sector and Biotechnology industry. Its latest reported market figures as of October 2, 2026 were a USD 6.10 Nasdaq quote, USD 7.7 million market capitalization and a USD 4.91 to USD 34.25 52-week range.